Payment overview · 2025
General Payments
$148.60
6 reported records · 4 companies
Healthcare provider profile · identity verified
Gregory Aaron Wallman, DO
Allopathic & Osteopathic Physicians|Internal Medicine · GLENVIEW, IL · NPI 1043324643
Verified facts
What the public records show
CMS Open Payments records show Gregory Aaron Wallman, DO received $148.60 in general payments during 2025 across 6 reported records.
Axsome Therapeutics, Inc. accounted for 41.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 301 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $61.96 | 41.7% | 2 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $45.40 | 30.6% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $23.44 | 15.8% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $17.80 | 12.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $148.60 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $61.96 | 2 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $45.40 | 2 | 2025 |
Source payment records
|
|||||
| FLUZONE HIGH-DOSE Normalized: fluzone high dose |
Biological | SANOFI PASTEUR INC. | $45.40 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $23.44 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $17.80 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $17.80 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
43 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
301 | 55 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
39 | 38 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 756 | 204 |
| Levothyroxine Sodium | Levothyroxine Sodium | 558 | 120 |
| Amlodipine Besylate | Amlodipine Besylate | 371 | 108 |
| Eliquis | Apixaban | 301 | 55 |
| Losartan Potassium | Losartan Potassium | 299 | 91 |
| Metoprolol Succinate | Metoprolol Succinate | 268 | 75 |
| Tamsulosin Hcl | Tamsulosin Hcl | 254 | 64 |
| Omeprazole | Omeprazole | 249 | 75 |
| Pantoprazole Sodium | Pantoprazole Sodium | 237 | 60 |
| Lisinopril | Lisinopril | 225 | 59 |
| Gabapentin | Gabapentin | 219 | 50 |
| Metformin Hcl | Metformin Hcl | 198 | 57 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 189 | 57 |
| Simvastatin | Simvastatin | 183 | 55 |
| Furosemide | Furosemide | 178 | 43 |
| Hydrochlorothiazide | Hydrochlorothiazide | 176 | 52 |
| Escitalopram Oxalate | Escitalopram Oxalate | 171 | 48 |
| Sertraline Hcl | Sertraline Hcl | 152 | 35 |
| Duloxetine Hcl | Duloxetine Hcl | 141 | 24 |
| Carvedilol | Carvedilol | 140 | 30 |
| Donepezil Hcl | Donepezil Hcl | 122 | 28 |
| Warfarin Sodium | Warfarin Sodium | 118 | 16 |
| Metoprolol Tartrate | Metoprolol Tartrate | 115 | 30 |
| Allopurinol | Allopurinol | 114 | 31 |
| Alprazolam | Alprazolam | 103 | 28 |
| Finasteride | Finasteride | 103 | 23 |
| Jardiance | Empagliflozin | 98 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 95 | 18 |
| Trazodone Hcl | Trazodone Hcl | 94 | 22 |
| Potassium Chloride | Potassium Chloride | 93 | 23 |
| Quetiapine Fumarate | Quetiapine Fumarate | 90 | 15 |
| Ezetimibe | Ezetimibe | 89 | 24 |
| Spironolactone | Spironolactone | 83 | 24 |
| Pravastatin Sodium | Pravastatin Sodium | 81 | 21 |
| Lorazepam | Lorazepam | 74 | 21 |
| Metformin Hcl Er | Metformin Hcl | 68 | 18 |
| Bupropion Xl | Bupropion Hcl | 67 | 19 |
| Montelukast Sodium | Montelukast Sodium | 67 | 19 |
| Azithromycin | Azithromycin | 65 | 56 |
| Mirtazapine | Mirtazapine | 63 | 14 |
| Divalproex Sodium | Divalproex Sodium | 62 | suppressed |
| Prednisone | Prednisone | 62 | 21 |
| Zolpidem Tartrate | Zolpidem Tartrate | 62 | 27 |
| Memantine Hcl | Memantine Hcl | 57 | suppressed |
| Methylprednisolone | Methylprednisolone | 56 | 45 |
| Meloxicam | Meloxicam | 54 | 26 |
| Risperidone | Risperidone | 54 | suppressed |
| Synthroid | Levothyroxine Sodium | 53 | 12 |
| Ramipril | Ramipril | 52 | 12 |
| Ozempic | Semaglutide | 51 | 11 |
| Xarelto | Rivaroxaban | 50 | suppressed |
| Famotidine | Famotidine | 49 | 16 |
| Valsartan | Valsartan | 49 | 12 |
| Entresto | Sacubitril/Valsartan | 48 | suppressed |
| Trulicity | Dulaglutide | 48 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 46 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 46 | 12 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 44 | 26 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 43 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 41 | 15 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 40 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 40 | 26 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 40 | 11 |
| Bupropion Hcl Sr | Bupropion Hcl | 39 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 39 | 38 |
| Aripiprazole | Aripiprazole | 38 | suppressed |
| Januvia | Sitagliptin Phosphate | 38 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 37 | suppressed |
| Clonazepam | Clonazepam | 37 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 35 | 26 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 35 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 34 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Bumetanide | Bumetanide | 33 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 33 | suppressed |
| Latanoprost | Latanoprost | 33 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 33 | suppressed |
| Atenolol | Atenolol | 32 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 32 | 32 |
| Digoxin | Digoxin | 31 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 31 | suppressed |
| Ursodiol | Ursodiol | 30 | suppressed |
| Levetiracetam | Levetiracetam | 29 | suppressed |
| Pregabalin | Pregabalin | 29 | suppressed |
| Amoxicillin | Amoxicillin | 28 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 28 | suppressed |
| Lamotrigine | Lamotrigine | 28 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 28 | suppressed |
| Celecoxib | Celecoxib | 27 | 12 |
| Cephalexin | Cephalexin | 26 | 24 |
| Lansoprazole | Lansoprazole | 26 | suppressed |
| Myrbetriq | Mirabegron | 26 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 26 | 22 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 25 | 21 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 25 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 25 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 24 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 24 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 23 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 21 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 21 | 18 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 20 | suppressed |
| Glipizide | Glipizide | 20 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 20 | suppressed |
| Diazepam | Diazepam | 19 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 19 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Baclofen | Baclofen | 18 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 18 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 18 | suppressed |
| Glimepiride | Glimepiride | 18 | suppressed |
| Hydrocortisone | Hydrocortisone | 18 | 14 |
| Ipratropium Bromide | Ipratropium Bromide | 18 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Xifaxan | Rifaximin | 18 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 17 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 16 | suppressed |
| Mesalamine | Mesalamine | 16 | suppressed |
| Olanzapine | Olanzapine | 16 | suppressed |
| Methotrexate | Methotrexate Sodium | 15 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 15 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 14 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | 11 |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Galantamine Er | Galantamine Hbr | 13 | suppressed |
| Ranolazine Er | Ranolazine | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Torsemide | Torsemide | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Enulose | Lactulose | 12 | suppressed |
| Lactulose | Lactulose | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 12 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 11 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 11 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 11 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $148.60 · 6 records | Axsome Therapeutics, Inc. | AREXVY, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FLUZONE HIGH-DOSE, NURTEC ODT, SHINGRIX, Symbravo | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error